Loading clinical trials...
Loading clinical trials...
To demonstrate efficacy and dose-response of NS 2330 versus placebo in patients with early Parkinson's Disease in 14 weeks of treatment, and to investigate the safety and tolerability of NS 2330 in th...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Boehringer Ingelheim
NCT07187843 · Parkinson Disease, Parkinsonian Disorders, and more
NCT07545473 · Dementia, Neurodegenerative Diseases, and more
NCT07543861 · Parkinson Disease
NCT05748028 · Parkinson Disease, Multiple System Atrophy
NCT07495462 · Parkinson Disease (PD)
Pivotal Reaserch Centers
Peoria, Arizona
Boehringer Ingelheim Investigational Site
Tucson, Arizona
PMDI
Fountain Valley, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions